

Giovanni G1 Lapadula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428200/publications.pdf>

Version: 2024-02-01

160
papers

6,538
citations

53794

45
h-index

74163

75
g-index

163
all docs

163
docs citations

163
times ranked

7736
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 754-763.	0.9	739
2	EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 620-628.	0.9	559
3	Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. <i>Osteoarthritis and Cartilage</i> , 2003, 11, 551-560.	1.3	223
4	Obesity and reduction of the response rate to anti-tumor necrosis factor $\hat{\pm}$ in rheumatoid arthritis: An approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013, 65, 94-100.	3.4	170
5	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	2.5	158
6	The pathophysiology of osteoarthritis. <i>Aging Clinical and Experimental Research</i> , 2003, 15, 364-372.	2.9	153
7	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	5.8	146
8	Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. <i>British Journal of Rheumatology</i> , 2002, 41, 1413-1418.	2.3	125
9	Laser-Evoked Potentials Habituation in Fibromyalgia. <i>Journal of Pain</i> , 2011, 12, 116-124.	1.4	101
10	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.9	96
11	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , 2016, 35, 1281-1286.	2.2	95
12	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
13	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	3.5	89
14	Longterm Retention of Tumor Necrosis Factor- $\hat{\pm}$ Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. <i>Journal of Rheumatology</i> , 2012, 39, 1179-1184.	2.0	87
15	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , 2016, 35, 1683-1689.	2.2	83
16	Obesity and Inflammation – Targets for OA Therapy. <i>Current Drug Targets</i> , 2010, 11, 586-598.	2.1	82
17	Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. <i>Hepatology</i> , 2015, 62, 40-46.	7.3	82
18	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82

#	ARTICLE	IF	CITATIONS
19	Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. <i>Journal of Rheumatology</i> , 2008, 35, 1944-9.	2.0	82
20	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-21.	3.0	79
21	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. <i>Autoimmunity Reviews</i> , 2015, 14, 1-9.	5.8	79
22	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	5.6	75
23	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 380.	3.5	72
24	Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1189.	4.1	71
25	The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 1-10.	2.1	69
26	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1743-1748.	0.9	68
27	Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. <i>Arthritis and Rheumatism</i> , 2005, 52, 3319-3321.	6.7	67
28	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , 2014, 13, 751-755.	5.8	67
29	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015, 54, 792-797.	1.9	67
30	Adalimumab in the Treatment of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 33-48.	2.1	65
31	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2018, 37, 2233-2240.	2.2	64
32	Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features. <i>Journal of Neurology</i> , 2014, 261, 461-472.	3.6	61
33	Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations. <i>Journal of rheumatology Supplement</i> , The, 2014, 91, 41-46.	2.2	61
34	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2018, 7, 504.	2.4	61
35	Obesity reduces the drug survival of second line biological drugs following a first TNF- α inhibitor in rheumatoid arthritis patients. <i>Joint Bone Spine</i> , 2015, 82, 187-191.	1.6	58
36	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.9	56

#	ARTICLE	IF	CITATIONS
37	Gastrointestinal symptoms and motility disorders in patients with systemic sclerosis. <i>BMC Gastroenterology</i> , 2008, 8, 7.	2.0	55
38	Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1121-1126.	0.9	55
39	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. <i>Autoimmunity Reviews</i> , 2016, 15, 447-450.	5.8	54
40	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. <i>Medicine (United States)</i> , 2015, 94, e1528.	1.0	51
41	Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. <i>Clinical Rheumatology</i> , 2015, 34, 1141-1143.	2.2	51
42	Bosentan fosters microvascular de-remodelling in systemic sclerosis. <i>Clinical Rheumatology</i> , 2012, 31, 1723-1725.	2.2	50
43	Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 11-32.	2.1	50
44	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. <i>Frontiers in Immunology</i> , 2017, 8, 200.	4.8	50
45	Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. <i>Arthritis and Rheumatism</i> , 2005, 52, 2519-2520.	6.7	48
46	Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial. <i>Journal of Rheumatology</i> , 2014, 41, 286-292.	2.0	47
47	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 249-252.	0.9	46
48	The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. <i>Current Medical Research and Opinion</i> , 2005, 21, 327-332.	1.9	43
49	Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1150-1154.	3.0	42
50	Extracorporeal shock waves down-regulate the expression of interleukin-10 and tumor necrosis factor-alpha in osteoarthritic chondrocytes. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 16.	1.9	38
51	Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid. <i>Rheumatology</i> , 2009, 48, 773-778.	1.9	37
52	Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 108-114.	3.4	37
53	Clinical diagnosis found in patients with Raynaud's phenomenon: a multicentre study. <i>Rheumatology International</i> , 1998, 18, 17-20.	3.0	36
54	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. <i>Clinical Rheumatology</i> , 2017, 36, 2063-2069.	2.2	36

#	ARTICLE	IF	CITATIONS
55	Long-Term Retention Rate of Anakinra in Adult Onset Stillé™s Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
56	Chondrocyte phenotyping in human osteoarthritis. <i>Clinical Rheumatology</i> , 1998, 17, 99-104.	2.2	33
57	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. <i>Medicine (United States)</i> , 2015, 94, e1858.	1.0	31
58	Two-year survival rates of anti-TNF-Î± therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 192-199.	1.1	30
59	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	30
60	Increased Bcl-2/p53 ratio in human osteoarthritic cartilage: a possible role in regulation of chondrocyte metabolism. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 217-221.	0.9	29
61	The Inhibitor of Costimulation of T Cells: Abatacept. <i>Journal of rheumatology Supplement</i> , The, 2012, 89, 100-102.	2.2	29
62	Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-Î± therapy. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 41-44.	1.1	29
63	Leucocytoclastic vasculitis as onset symptom of ulcerative colitis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 785-786.	0.9	28
64	Chemerin/ChemR23 pathway: a system beyond chemokines. <i>Arthritis Research and Therapy</i> , 2011, 13, 104.	3.5	28
65	Old and New Antirheumatic Drugs and the Risk of Hepatotoxicity. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 622-628.	2.0	28
66	PFAPA syndrome and Behçetâ€™s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. <i>Clinical Rheumatology</i> , 2016, 35, 501-505.	2.2	28
67	A Case of Osteonecrosis of the Jaw in a Patient with Crohnâ€™s Disease Treated with Infliximab. <i>American Journal of Case Reports</i> , 2017, 18, 1351-1356.	0.8	28
68	Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). <i>Clinical Rheumatology</i> , 2018, 37, 667-675.	2.2	28
69	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	2.6	27
70	Untangling the Web of Systemic Autoinflammatory Diseases. <i>Mediators of Inflammation</i> , 2014, 2014, 1-15.	3.0	25
71	Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature. <i>Clinical Rheumatology</i> , 2015, 34, 391-395.	2.2	25
72	Orofacial Manifestations and Temporomandibular Disorders of Sjögren Syndrome: An Observational Study. <i>International Journal of Medical Sciences</i> , 2018, 15, 475-483.	2.5	25

#	ARTICLE	IF	CITATIONS
73	Isolated sternoclavicular joint arthritis in heroin addicts and/or HIV positive patients: Three cases. <i>Clinical Rheumatology</i> , 1993, 12, 422-425.	2.2	24
74	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii42-vii53.	1.9	24
75	Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. <i>Clinical Therapeutics</i> , 2017, 39, 1026-1039.	2.5	23
76	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 531-8.	0.8	23
77	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	22
78	Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 224-228.	1.1	22
79	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 1-4.	0.8	22
80	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
81	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	2.2	19
82	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. <i>Journal of Rheumatology</i> , 2016, 43, 911-917.	2.0	19
83	Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S102-6.	0.8	19
84	Early alteration of synovial membrane in osteoarthritis. <i>Clinical Rheumatology</i> , 1988, 7, 214-219.	2.2	17
85	Microscopic polyangiitis associated with primary biliary cirrhosis. <i>Journal of Rheumatology</i> , 2003, 30, 2710-2.	2.0	17
86	Update on the Medical Management of Gastrointestinal Behçet's Disease. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	3.0	16
87	Coexisting Psoriatic Arthritis, Gout, and Chondrocalcinosis: CASE REPORT. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 306-309.	1.1	15
88	Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: Analytical performance and clinical correlations. <i>Clinica Chimica Acta</i> , 2005, 355, 137-144.	1.1	15
89	Digital laser doppler flowmetry may discriminate "limited" from "diffuse" systemic sclerosis. <i>Microvascular Research</i> , 2010, 80, 221-226.	2.5	15
90	Erasmus syndrome in a marble worker. <i>Reumatismo</i> , 2015, 67, 116-122.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DELphi in psoriatic Arthritis (IDEA). <i>Reumatismo</i> , 2016, 68, 126-136.	0.9	15
92	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 525-530.	1.6	15
93	Patients’; physicians’; nurses’; and pharmacists’; preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2153-2168.	1.8	15
94	Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment. <i>Clinical Rheumatology</i> , 2019, 38, 2355-2362.	2.2	15
95	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 68-73.	0.8	15
96	Serum amyloid-A in Behçet's disease. <i>Clinical Rheumatology</i> , 2014, 33, 1165-1167.	2.2	14
97	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	1.6	14
98	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
99	Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response. <i>Drug Development Research</i> , 2014, 75, S77-80.	2.9	13
100	Influence of TNF- α inhibition on oxidative stress of rheumatoid arthritis patients. <i>Reumatismo</i> , 2015, 67, 97-102.	0.9	12
101	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 424-9.	0.8	11
102	Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. <i>European Journal of Clinical Investigation</i> , 2006, 36, 73-77.	3.4	10
103	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. <i>Clinical Rheumatology</i> , 2014, 33, 31-37.	2.2	10
104	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 19-23.	2.2	10
105	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 649-655.	0.8	10
106	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 762-767.	0.8	10
107	Isolated thrombocytopenia associated with low dose methotrexate therapy. <i>Clinical Rheumatology</i> , 1997, 16, 429-430.	2.2	9
108	Phenotype of chondrocytes in osteoarthritis. <i>Biorheology</i> , 2008, 45, 411-413.	0.4	9

#	ARTICLE	IF	CITATIONS
109	Intra-articular therapy with tumor necrosis factor- α antagonists: an update. <i>Reumatismo</i> , 2014, 65, 257.	0.9	9
110	Management of Small Vessel Vasculitides. <i>Current Rheumatology Reports</i> , 2016, 18, 36.	4.7	9
111	The UltraSound-Clinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 619-629.	3.4	9
112	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. <i>European Journal of Internal Medicine</i> , 2019, 66, 57-61.	2.2	9
113	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 895-902.	1.8	9
114	Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e31-e31.	0.9	8
115	Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. <i>Joint Bone Spine</i> , 2016, 83, 721-725.	1.6	8
116	Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?. <i>Clinical Drug Investigation</i> , 2019, 39, 565-575.	2.2	8
117	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1018-1028.	0.8	8
118	Structural and oxidative modifications of erythrocyte ghosts in patients with primary biliary cirrhosis: relation with the disease stage and effect of bile acid treatment. <i>European Journal of Clinical Investigation</i> , 2003, 33, 868-874.	3.4	7
119	Metabolic Activity of Chondrocytes in Human Osteoarthritis as a Result of Cell-extracellular Matrix Interactions. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 9-12.	3.4	7
120	Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series. <i>Rheumatology International</i> , 2012, 32, 3281-3284.	3.0	7
121	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021, 48, 48-57.	2.0	7
122	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 93-97.	0.8	7
123	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , 2018, 20, 438-441.	0.1	7
124	Carpal tunnel syndrome: A review. <i>Clinical Rheumatology</i> , 1997, 16, 596-603.	2.2	6
125	Functional Impairments of Microcirculation in HIV-Positive Patients: A Laser Doppler Fluxometry-Based Investigation. <i>HIV Clinical Trials</i> , 2008, 9, 428-433.	2.0	6
126	Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients. <i>Autoimmunity Highlights</i> , 2011, 2, 29-33.	3.9	6

#	ARTICLE	IF	CITATIONS
127	Different switching rate of anti-TNF- α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. <i>Joint Bone Spine</i> , 2014, 81, 458-459.	1.6	6
128	Mitochondrial Disease Mimicking Polymyositis: A Case Report. <i>Clinical Rheumatology</i> , 2002, 21, 411-414.	2.2	5
129	Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies. <i>Reumatismo</i> , 2014, 66, 215-223.	0.9	5
130	Retinal Vessels Thrombosis as Onset Manifestation of Systemic Sclerosis: 3 Clinical Cases. <i>Journal of Rheumatology</i> , 2014, 41, 2495-2496.	2.0	5
131	Delights and letâ€downs in the management of tumor necrosis factor receptorâ€associated periodic syndrome: the canakinumab experience in a patient with a highâ€penetrance T50M variant. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 473-475.	1.9	5
132	Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis. <i>Journal of International Medical Research</i> , 2016, 44, 28-32.	1.0	5
133	Do dermatomyositis and polymyositis affect similar thigh muscles? A comparative MRI-based study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1098-1100.	0.8	5
134	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 660-665.	0.8	5
135	Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 130-131.	0.8	5
136	Monoclonal antibody investigation in rheumatoid arthritis: presence of a T cell subpopulation bearing a double marker. <i>Clinical Rheumatology</i> , 1984, 3, 137-144.	2.2	4
137	Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue diseaseâ€like onset. <i>Clinical Rheumatology</i> , 2006, 25, 919-922.	2.2	4
138	A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. <i>Reumatismo</i> , 2014, 65, 298.	0.9	4
139	Efficacy and Safety of Certolizumab Pegol in Rheumatoid Arthritis: Meeting Rheumatologistsâ€™ Requirements in Routine Clinical Practice. <i>BioDrugs</i> , 2014, 28, 25-37.	4.6	4
140	Recovery of Barium Swallow Radiographic Abnormalities in a Patient With Dermatomyositis and Severe Dysphagia After High-Dose Intravenous Immunoglobulins. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 227.	0.9	4
141	Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy. <i>Clinical Rheumatology</i> , 2016, 35, 1923-1929.	2.2	4
142	No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 90-96.	1.9	4
143	The Acute Phase Protein Profile in Inflammatory Arthropathies. <i>Scandinavian Journal of Rheumatology</i> , 1987, 16, 90-93.	1.1	3
144	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease. <i>Pediatric Rheumatology</i> , 2015, 13, .	2.1	3

#	ARTICLE	IF	CITATIONS
145	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. Archives of Rheumatology, 2020, 35, 163-169.	0.9	3
146	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. Clinical Rheumatology, 2021, 40, 4039-4047.	2.2	3
147	Chondrocytes-ECM Interactions in Human Osteoarthritis. Advances in Experimental Medicine and Biology, 1999, 455, 413-417.	1.6	3
148	Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: a case series and review of the literature. International Journal of Rheumatic Diseases, 2015, 18, 908-912.	1.9	2
149	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link intertwining obesity and osteoarthritis?. Annals of the Rheumatic Diseases, 2015, 74, e70-e70.	0.9	2
150	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmunity Reviews, 2018, 17, 1251-1258.	5.8	2
151	Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years. Clinical and Experimental Rheumatology, 2015, 33, 524-30.	0.8	2
152	Present Status and New Perspectives in Non-Steroidal Anti-Inflammatory Drugs Therapy. Scandinavian Journal of Rheumatology, 1987, 16, 75-83.	1.1	1
153	Response of Cartilage Oligomeric Matrix Protein to Monoclonal Antibody Drugs in Patients with Rheumatoid Arthritis. Laboratory Medicine, 2009, 40, 645-650.	1.2	1
154	Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman. Reumatismo, 2015, 67, 17-20.	0.9	1
155	Comment on "Tumor necrosis factor- α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study". Clinical Rheumatology, 2016, 35, 839-840.	2.2	1
156	Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry. Indian Journal of Rheumatology, 2019, 14, 271.	0.4	1
157	Protein measurement of inflammation. Research in Clinic and Laboratory, 1981, 11, 223-7.	0.3	1
158	L'efficacité diminue le maintien thérapeutique des traitements biologiques de seconde ligne après l'arrêt d'un anti-TNF de première ligne au cours de la polyarthrite rhumatoïde. Revue Du Rhumatisme (Edition) Tj ET 00 0 0 rgt /Overlo	0.0	0
159	Polyarthrite rhumatoïde: réponse clinique précoce sous certolizumab prédictive d'une faible activité de la maladie à un an en situation de "vraie vie". Évaluation du registre italien GISEA. Revue Du Rhumatisme (Edition Française), 2017, 84, 511-515.	0.0	0
160	Prise en charge de l'infection par le virus de l'hépatite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne. Revue Du Rhumatisme (Edition Française), 2018, 85, 115-120.	0.0	0